Company profile
Parabilis Medicines, Inc.
NASDAQ: PBLS · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH 24DQ —GM —SS 45
v0.1 · 35/100 weight · pillars only
↑ workforce scale, market scale · ↓ listing tenure, disclosure history
Methodology →Revenue TTM
$148.0k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$145.9M
Employees
145
as of 2026-08-01
Market cap
$111.3M
as of 2026-08-01
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$145.9M-$145.9M2025
Operating income-$152.1M-$152.1M2025
Total assets$80.8M$80.8M2025
Liabilities$97.3M$97.3M2025
Equity-$16.5M-$16.5M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Parabilis Medicines, Inc.’s revenue?
Parabilis Medicines, Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Helix BioPharma Corp.——Vivani Medical, Inc.33DFractyl Health, Inc.28DRevium Recovery Inc.——HST Global, Inc.——MAIA Biotechnology, Inc.34DNeighbors
Middlesex →Key facts
CEOMathai Mammen
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: PBLS
Employees145
IPO date2026-06-10
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.